PRESTIGE-AF at ESOC19 in pictures

The European Stroke Organisation Conference (ESOC) is a premier European forum for stroke research and rapidly becoming the global platform for the release of major trial data.

The PRESTIGE-AF team went to ESOC 2019 in Milan of which several members of the team presented and showcased. Alongside the main conference, the PRESTIGE-AF local investigators were invited to a meeting specific to PRESTIGE-AF activities and project status.

Here is the conference in photos taken by the PRESTIGE-AF team. Enjoy!

This and above: The team arriving for the first day of ESOC
Prof Stephanie Debette (Universite de Bordeaux, PRESTIGE-AF consortium member and leader of the genetics component) on the panel as a mentor giving feedback on young researchers’ protocols. Also in the photo (far left) is Rustam Al-Shahi Salman (University of Edinburgh, Edinburgh, Scotland) who is a leader in haemorrhage research and part of the RESTART trial.
This and above: Prof Stephanie Debette presenting at the conference with “My Journey, Highs and Lows in Stroke Research”.
This and above: Dr Eleni Korompoki (member of the Imperial College London team for PRESTIGE-AF team) presenting in the transient ischemic attack (TIA) session.
ESOC day 2!
Prof Roland Veltkamp (Imperial College London, UK) in the controversies in stroke debate. Prof Veltkamp was arguing in the affirmative for starting anticoagulants after intracerebral hemorrhage (ICH).
Prof Roland Veltkamp (Imperial College London, UK) above] in the controversies in stroke debate with Prof Karin Klijn (Radboud University) [here] – Prof Veltkamp was arguing in the affirmative for starting anticoagulants after intracerebral hemorrhage (ICH) with Prof Klijn as the opposing.
ESOC award winners including PRESTIGE-AF’s very own Prof Stephanie Debette!
PRESTIGE/AF collaborator Dr Wang discussing the burden of stroke over the next 30 years
The PRESTIGE-AF team were eagerly anticipating the presentation of the results of the PRACTISE Trial. Amongst a full house in the “Large Clinical Trials” session the PRACTISE trial demonstrated that when patients were given multimodal imaging, 1 in 5 patients were given IV thrombolysis without any reduction in patient outcomes. Extra imaging may reduce unnecessary thrombolysis in patients.
The PRESTIGE-AF team were eagerly anticipating the presentation of the results of the PRACTISE Trial. Amongst a full house in the “Large Clinical Trials” session the PRACTISE trial demonstrated that when patients were given multimodal imaging, 1 in 5 patients were given IV thrombolysis without any reduction in patient outcomes. Extra imaging may reduce unnecessary thrombolysis in patients.
Results of sub analysis of WAKE-UP trial: thrombolysis is effective in large vessel occlusion stroke patients with unknown symptom onset and gives twice the likelihood of a favourable outcome.
Conference ends at 15.45. It’s a wrap! We will see PRESTIGE-AF next year in Vienna!
Posted: 25th June 2019
See All Articles

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 754517